The pituitary gland may give rise to a range of etiologically distinct tumors, necessitating a diverse set of multidisciplinary therapeutic approaches. Radiotherapy is clinically indicated in approximately 50% of cancer patients worldwide . Since the advent of highly conformal, stereotactic radiotherapy approaches, stereotactic radiosurgery (SRS) has become a standard treatment option for residual or recurrent nonfunctioning pituitary adenomas . After 5years in retrospective series [3-6], reported local tumor control rates are high, at more than 90%. In the setting of functioning pituitary adenomas, radiosurgery is generally reserved for residual, recurrent, or refractory disease . This chapter details indications, risks, and benefits of pituitary radiotherapy, as well as differences in treatment approaches between SRS, conventionally fractionated external beam radiotherapy, and proton therapy.
|Original language||English (US)|
|Title of host publication||The Pituitary|
|Number of pages||12|
|State||Published - Jan 1 2022|
- Stereotactic radiosurgery
ASJC Scopus subject areas